CompanyTempus, Inc.
United States of America
Tempus is a technology company that provides genomic and transcriptomic sequencing services and analyzes somatic and germline molecular data along with therapeutic data to empower physicians to make data-driven decisions.
Private/Public:
private
Phone:800.739.4137
Email:[email protected]
Website:https://www.tempus.com/
Address:600 West Chicago Ave. Ste 510 Chicago, IL 60642, United States of America
2015
Since
1
Country
7
Top Service Categories
84
Sub-Service Categories
Top Services
Clinical
Clinical Development Services
Clinical Study Types Serviced
Discovery and Preclinical
Chemistry/Discovery Tech./In silico services
Efficacy In Vitro
Research Supplies
Life Sciences Supplies/Reagents
Diagnostics
Diagnostic assay development/manufacturing
Diagnostic Imaging Services/Technologies
Diagnostic Testing Services - Genomic/Non-genomic
- Clinical Diagnostic Laboratory Services
- Clinical trial testing services
- Diagnostic Testing Services - Molecular/genomic
- Cancer Genetic Testing Services
- Cancer Screening/Profiling/Panels Testing
- Cancer Transcriptome testing
- Hematological malignancies genetic testing
- Hereditary cancer panels
- Immuno-oncology molecular testing
- Neoantigen detection
- Paired tumor/normal analysis of DNA and RNA
- Solid cancer genetic testing
- Tumor mutational burden (TMB) testing
- WES/WGS/WTS NGS cancer testing panels
- Cancer Screening/Profiling/Panels Testing
- Infectious disease genetic testing
- Pharmacogenetic (PGx) Testing Services
- Transplantation genetic testing
- Cancer Genetic Testing Services
- Diagnostic Testing Services - nongenomic
- Laboratory Support Services
Medical and Delivery Devices
Diagnostic Equipment Offerings
United States of America
- (20.May.2022) Tempus Launches Psychiatric Real-World Data Program to Advance Personalized Medicine
- (09.May.2022) Aadi Bioscience Announces Collaborations With Next Generation Sequencing Leaders
- (06.May.2022) Tempus Announces Agreement With the United States Department of Veterans Affairs National Precision Oncology Program to Expand Access to Genomic Testing for Veterans With Cancer
- (12.Apr.2022) Pyramid Biosciences Announces TIME Trial Program Collaboration With Tempus for Patients With NTRK Fusion Solid Tumors
- (21.Mar.2022) Tempus' EDGE Platform Leverages Data & AI to Identify Therapeutic Options for Patients Earlier in the Treatment Journey
- (07.Mar.2022) Kinnate Biopharma Inc. Presents Data From Its Real-World Clinico-Genomic Study Collaboration With Tempus at the Virtual ESMO Targeted Anticancer Therapies Congress
- (08.Feb.2022) Tempus Announces the Acquisition of Highline Sciences
- (18.Jan.2022) A2 Bio to Present at ASCO-GI 2022 on Use of Next Generation Sequencing (NGS) to Identify GI Cancer Patients for Future Tmod CAR T Therapy
- (13.Jan.2022) Tempus Announces Open Enrollment for Study in Collaboration with GSK to Evaluate Niraparib in Advanced Solid Tumor Patients with PALB2 Mutations
- (13.Jan.2022) Tempus Announces Open Enrollment for Study in Collaboration With GSK to Evaluate Niraparib in Advanced Solid Tumor Patients With PALB2 Mutations
- (01.Dec.2021) Tempus Announces Agreement With Janssen R&D to Leverage AI/ML and Real-World Evidence to Enhance the Discovery and Development of Oncology Therapies
- (19.Nov.2021) Tempus Signs Strategic Collaboration Agreement With AstraZeneca to Advance Oncology Therapeutics
- (18.Nov.2021) Tempus Accelerates Its EHR Integration Scope with Epic
- (16.Nov.2021) Tempus Incorporates OncoKB Data and NCCN Guidelines Into Its Clinical Reports
- (08.Nov.2021) Kronos Bio and Tempus Announce Multi-Year Collaboration to Provide Kronos Bio With Access to Tempus' Platform
- (26.Oct.2021) Tempus Introduces a New, Predictive Diagnostic Test to Its Growing Collection of Algorithms
- (09.Sep.2021) 'Molecular Twin' Initiative Will Help Advance Precision Cancer Treatment
- (17.Aug.2021) Tempus Submits PMA Application to the FDA for Its xT-Onco Assay
- (04.Aug.2021) Tempus Announces New Genomic Sequencing Lab in Research Triangle Park in Durham, NC
- (28.Jul.2021) Tempus Unveils Its Scalable Tumor Organoid Screening Platform in Cell Reports Study
- (12.Jul.2021) Tempus xF Liquid Biopsy Assay Demonstrates Extensive Analytical and Clinical Validity in NPJ Precision Oncology Study
- (08.Jul.2021) Tempus Announces Leadership Team Expansion Including Chief Commercial Officer and Chief Financial Officer
- (03.Jun.2021) Rain Therapeutics Announces Collaboration With Tempus for Genomic Analysis in Planned MDM2-Amplified Phase 2 Basket Trial of RAIN-32